December began with what looks like an end-of-year venture capital dealmaking rush, including an $80m Series C round to fund Naurex's drug candidates for depression and central nervous system (CNS) disorders plus four other sizeable US biotechnology deals.
Biotech venture capital investment in 2014 already is poised to outpace 2013's total and VC investors in the US came...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
